Although the more detailed molecular mechanism of activation of NLRP3 inflammasomes remains to be clarified until now, and the research on the treatment of T2DM targeting NLRP3 inflammasomes is filled with a large number of unknown challenges, we still believe that challenges are often accompanied by opportunities. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.